Menopause comprises approximately one third of a woman’s life and is conditioned by hormonal changes that directly impact her quality of life. The disappearance of ovulation and the decrease in estrogen and progesterone levels cause the climacteric syndrome that accompanies this stage. Common symptoms include hot flashes, night sweats, and sleep disturbances. Genitourinary symptoms, such as vulvovaginal atrophy and dryness, are also very common and have a great impact on a woman’s quality of life.
Hormone therapy has been the treatment of choice for managing these symptoms for decades. However, for women seeking more natural or non-pharmacological treatments, patients and health professionals are demanding different alternatives.
Hand in hand with specialists in the area of Gynecology, Italfarmaco Group, a benchmark in the research and development of medicines, food supplements and health products committed to Women’s Health since its inception, has studied the evolution of these symptoms with products developed by the company in a group of postmenopausal women, launching the Flavie study.
Improvement in quality of life from the first month of taking Flavia Nocta
Phytoestrogen-based therapies, such as isoflavones, are among the most common alternatives to hormone therapy for the management of vasomotor symptoms in menopause. Flavie is a study that evaluated the effect of Flavia Nocta® (soy isoflavones, 8-prenylnaringenin and melatonin) on hot flashes and quality of life in 44 postmenopausal women. Early on, at 4 weeks, a significant decrease in the number of hot flashes was observed, particularly those of greater intensity, reaching a 76.5% reduction at 12 weeks of administration. These women presented a marked and progressive improvement in their quality of life related to vasomotor symptoms, and also documented other physical and psychosocial improvements.
The Flavie study evaluated the effect of Flavia Nocta®, observing a significant decrease in hot flashes and a better quality of life
The results of this study have been presented at various international conferences throughout 2021, including: the conference on Controversies in Obstetrics, Gynecology and Infertility (COGI) or the conference of the Italian Society of Gynecology and Obstetrics (SIGO). The results of the Flavie study have been submitted for publication in an international journal in 2022.
.
